Latest Wockhardt News
Stay Informed on Wockhardt Stock News: Access the latest Wockhardt stock news, industry updates, and quick information on Wockhardt stock buybacks,Wockhardt results, Wockhardt company analysis, Wockhardt live prices, Wockhardt dividends, Wockhardt bonus share, board meetings, lifetime highs, Wockhardt targets, lows, and growth stories with AI—all in one place.
Business Line
Wockhardt clinches BIRAC innovator award for novel antibiotic
The drug addresses a significant medical need, as existing treatments like Azithromycin face resistance issues or lack comprehensive coverage of respiratory pathogens
•
Mon, Sep 16, 2024
Business Standard
Congress vs Sebi chief Buch: Trading strategies in M&M, Pidilite, Wockhardt
After ICICI and Wockhardt; M&M, Dr.Reddy's and Pidilite are the latest company names to be dragged in the Congress versus Sebi chief controversy. Here's a technical outlook on these stocks.
•
Tue, Sep 10, 2024
The Economic Times
Wockhardt has refuted allegations of conflict of interest and corruption made by the Congress party against SEBI chairperson Madhabi Puri Buch. The claims relate to rental payments by Carol Info Service, an affiliate of Wockhardt, which is involved in multiple cases with SEBI, including insider trading. Wockhardt termed the allegations as baseless and misleading.
•
Sat, Sep 7, 2024
Business Standard
Wockhardt denies Carol Info rent payment allegations, link with Sebi orders
Drug firm Wockhardt has denied allegations regarding payment of rent by Carol Info Services and its connection with certain orders passed by SEBI in relation to the company. "In this regard, we categorically deny these allegations and state that these allegations are completely baseless and misleading," Wockhardt said in a regulatory filing late Friday. It said the company has acted and continues to act in compliance with all applicable laws. On Friday, the Congress' media and publicity department head, Pawan Khera said that between 2018 and 2024, Madhabi Buch - as a whole-time member and later chairperson of Securities and Exchange Board of India (SEBI) - had been receiving rental income amounting to Rs 2.16 crore from Carol Info Services, a company affiliated to Wockhardt. Mumbai-based Wockhardt was being investigated by SEBI for various cases, including that of insider trading during 2023, he said at a press conference at the AICC headquarters in Delhi.
The Economic Times
Wockhardt denies allegations of rent payments connections to SEBI orders, claims them baseless
Congress leader Pawan Khera on Friday had accused Sebi chief Madhabi Puri Buch of conflict of interest with the pharma company.
•
Sat, Sep 7, 2024
CNBC TV18
Wockhardt refutes allegations of rent payments linked to SEBI orders, labels claims baseless
Shares of Wockhardt Ltd ended at ₹1,034.60 on Friday (September 6), down by ₹54.45, or 5.00% on the BSE.
•
Sat, Sep 7, 2024
Mint
Buch allegedly earned rent from Wockhardt firm while Sebi was probing the drugmaker
The Congress has accused Madhabi Puri Buch of receiving ₹2.17 crore in rental income from a firm linked to Wockhardt, which was under investigation for insider trading. This is the latest in a series of allegations targeting the Sebi chair related to her past roles and investments.
Business Standard
Congress launches fresh attack on Sebi chief Buch over rental income
Income of Rs 2.16 cr from firm linked to Wockhardt, a company under investigation
•
Fri, Sep 6, 2024
Business Standard
Wockhardt falls 5% after Congress alleges Sebi head of conflict of interest
This came after the Congress party accused Securities and Exchange Board of India (Sebi) chairperson Madhabi Puri Buch of a conflict of interest involving the pharmaceutical firm Wockhardt
•
Fri, Sep 6, 2024
The Economic Times
Wockhardt shares fall 5% as Congress accuses Sebi chief of conflict of interest, corruption
Wockhardt shares dropped 5% after Congress leader Pawan Khera accused SEBI chief Madhabi Puri Buch of corruption and insider trading. Khera alleged a conflict of interest due to Buch's property dealings with a Wockhardt subsidiary. Congress demands an independent inquiry to maintain trust in India's stock markets.
•
Fri, Sep 6, 2024
Business Standard
Mumbai-based Wockhardt to launch its novel antibiotic Zaynich by FY25-end
Global launch in FY26 after multinational clinical trial ends
•
Fri, Jun 28, 2024
The Economic Times
Wockhardt aims to launch antibiotic with USD 25 bn mkt potential by early FY26
With strong financial backing and successful research, Wockhardt is poised for the launch of Zaynich, an antibiotic targeting high resistance levels globally. The company's strategic pricing and partnership approaches enhance its market penetration, setting the stage for a significant impact on the pharmaceutical industry.
•
Fri, Jun 28, 2024